EA202190663A1 - Кристаллические формы агониста фарнезоидного х-рецептора - Google Patents

Кристаллические формы агониста фарнезоидного х-рецептора

Info

Publication number
EA202190663A1
EA202190663A1 EA202190663A EA202190663A EA202190663A1 EA 202190663 A1 EA202190663 A1 EA 202190663A1 EA 202190663 A EA202190663 A EA 202190663A EA 202190663 A EA202190663 A EA 202190663A EA 202190663 A1 EA202190663 A1 EA 202190663A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor agonist
crystalline forms
pharnesoid
trans
farnesoid
Prior art date
Application number
EA202190663A
Other languages
English (en)
Inventor
Николас Д. Смит
Роберт Менсфилд
Original Assignee
Метакрайн, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метакрайн, Инк. filed Critical Метакрайн, Инк.
Publication of EA202190663A1 publication Critical patent/EA202190663A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В изобретении описан агонист фарнезоидного Х-рецептора, транс-N-(3-(1-циклопропил-1H-пиразол-4-ил)фенил)-4-гидрокси-N-((транс-4-(4-метокси-3-метилфенил)циклогексил)метил)циклогексанкарбоксамид, включая кристаллические формы и его фармацевтически приемлемые соли, сольваты и составы.
EA202190663A 2018-09-18 2019-09-17 Кристаллические формы агониста фарнезоидного х-рецептора EA202190663A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862733007P 2018-09-18 2018-09-18
PCT/US2019/051605 WO2020061115A1 (en) 2018-09-18 2019-09-17 Crystalline forms of a farnesoid x receptor agonist

Publications (1)

Publication Number Publication Date
EA202190663A1 true EA202190663A1 (ru) 2021-08-13

Family

ID=69887984

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190663A EA202190663A1 (ru) 2018-09-18 2019-09-17 Кристаллические формы агониста фарнезоидного х-рецептора

Country Status (15)

Country Link
US (1) US20210347736A1 (ru)
EP (1) EP3852749A4 (ru)
JP (1) JP2022500395A (ru)
KR (1) KR20210064261A (ru)
CN (1) CN113056270A (ru)
AU (1) AU2019344905A1 (ru)
BR (1) BR112021004931A2 (ru)
CA (1) CA3112485A1 (ru)
CL (1) CL2021000631A1 (ru)
EA (1) EA202190663A1 (ru)
IL (1) IL281464A (ru)
MA (1) MA53671A (ru)
MX (1) MX2021003083A (ru)
SG (1) SG11202102586RA (ru)
WO (1) WO2020061115A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202110242YA (en) 2015-09-16 2021-10-28 Metacrine Inc Farnesoid x receptor agonists and uses thereof
CN113056271A (zh) 2018-09-18 2021-06-29 梅塔科林公司 法尼醇x受体激动剂及其用途
KR20220155596A (ko) * 2020-03-18 2022-11-23 메타크린, 인크. 파르네소이드 x 수용체 효능제의 제제
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1914205A (zh) * 2003-12-19 2007-02-14 葛兰素集团有限公司 吡唑并[3,4－b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途
PT1734970E (pt) * 2004-03-12 2015-03-11 Intercept Pharmaceuticals Inc Tratamento de fibrose utilizando ligandos de rfx
CA2642220A1 (en) * 2006-02-14 2007-08-23 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
EP2393811A1 (en) * 2009-02-04 2011-12-14 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
CN103391937A (zh) * 2010-12-20 2013-11-13 Irm责任有限公司 用于调控法尼醇x受体的组合物和方法
EP3350164A4 (en) * 2015-09-16 2019-03-27 Metacrine, Inc. X FARNESOID RECEPTOR AGONISTS AND USES THEREOF
EP3350166A4 (en) * 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
US10626081B2 (en) * 2015-09-16 2020-04-21 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
SG10202110242YA (en) * 2015-09-16 2021-10-28 Metacrine Inc Farnesoid x receptor agonists and uses thereof
JP6865743B2 (ja) * 2015-10-01 2021-04-28 フィルメニッヒ インコーポレイテッドＦｉｒｍｅｎｉｃｈ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｔｒｐｍ８の活性調節因子として有用な化合物
WO2017078928A1 (en) * 2015-11-06 2017-05-11 Salk Institute For Biological Studies Fxr agonists and methods for making and using
CA3056019A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof

Also Published As

Publication number Publication date
KR20210064261A (ko) 2021-06-02
WO2020061115A1 (en) 2020-03-26
CA3112485A1 (en) 2020-03-26
CN113056270A (zh) 2021-06-29
EP3852749A4 (en) 2022-08-24
BR112021004931A2 (pt) 2021-06-01
MA53671A (fr) 2021-07-28
EP3852749A1 (en) 2021-07-28
CL2021000631A1 (es) 2021-10-01
JP2022500395A (ja) 2022-01-04
SG11202102586RA (en) 2021-04-29
US20210347736A1 (en) 2021-11-11
MX2021003083A (es) 2021-05-27
AU2019344905A1 (en) 2021-04-29
IL281464A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
EA202190663A1 (ru) Кристаллические формы агониста фарнезоидного х-рецептора
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CO2020000193A2 (es) Compuestos antiproliferativos y métodos para utilizarlos
CU20200014A7 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
BR112018075597A2 (pt) derivados de carbamato de 2-amino-4-(amino substituído)fenila fluorado
DK3713919T3 (da) Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid
PH12019501068A1 (en) Crystalline forms of a magl inhibitor
MY179802A (en) Hydrochloride salt form for ezh2 inhibition
CL2020003174S1 (es) Dispositivo para administración de dosis.
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
CR20200116A (es) Compuestos de bisamida que activan el sarcómero y sus usos
PH12017501060A1 (en) Pharmaceutical combination comprising a selective s1p1 receptor agonist
DK2125736T3 (da) Substituerede acetophenoner egnede som PDE4-inhibitorer
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
EP4217352A4 (en) SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGUES AS MODULATORS OF THE CEREBLON PROTEIN
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
MX2020008076A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
CY1118886T1 (el) Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης
CL2022000881A1 (es) Formas cristalinas de estado sólido de un modulador selectivo de canales de potasio
CU20190095A7 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
EA202192453A1 (ru) Полиморфы и сокристаллы активатора кардиотропонина
MX2021005681A (es) Combinacion de un inhibidor de mcl-1 y midostaurina, usos y composiciones farmaceuticas de la misma.
CL2022000089A1 (es) Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il) -2-metil-2h- tetrazole-5-carboxamida.
CL2020000439A1 (es) Sales de un compuesto y sus formas cristalinas.